Autoantibody Profiles in Collagen Disease Patients with Interstitial Lung Disease (ILD): Antibodies to Major Histocompatibility Complex Class I-Related Chain A (MICA) as Markers of ILD.
Interstitial lung disease (ILD) is frequently associated with collagen disease. It is then designated as collagen vascular disease-associated ILD (CVD-ILD), and influences patients' prognosis. The prognosis of acute-onset diffuse ILD (AoDILD) occurring in patients with collagen disease is quite poor. Here, we report our investigation of auto-antibody (Ab) profiles to determine whether they may be useful in diagnosing CVD-ILD or AoDILD in collagen disease. Auto-Ab profiles were analyzed using the Lambda Array Beads Multi-Analyte System, granulocyte immunofluorescence test, Proto-Array Human Protein Microarray, AlphaScreen assay, and glutathione S-transferase capture enzyme-linked immunosorbent assay in 34 patients with rheumatoid arthritis (RA) with or without CVD-ILD and in 15 patients with collagen disease with AoDILD. The average anti-major histocompatibility complex class I-related chain A (MICA) Ab levels were higher in RA patients with CVD-ILD than in those without (P = 0.0013). The ratio of the average anti-MICA Ab level to the average anti-human leukocyte antigen class I Ab level (ie, MICA/Class I) was significantly higher in RA patients with CVD-ILD compared with those without (P = 4.47 × 10(-5)). To the best of our knowledge, this is the first report of auto-Ab profiles in CVD-ILD. The MICA/Class I ratio could be a better marker for diagnosing CVD-ILD than KL-6 (Krebs von den lungen-6).
Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan. ; Molecular and Genetic Epidemiology Laboratory, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
Hiroshi
H
Furukawa
Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan. ; Molecular and Genetic Epidemiology Laboratory, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
Shomi
S
Oka
Department of Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan. ; Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Fuchu, Japan.
Kota
K
Shimada
Technical Marketing Department, VERITAS Corporation, Tokyo, Japan.
Kiyoe
K
Masuo
Research and Development Department, Central Blood Institute, Japanese Red Cross Society, Tokyo, Japan.
Fumiaki
F
Nakajima
Proteo-Medicine Research Center, Ehime University, Toon.
Shunichi
S
Funano
Intergated Center for Science, Ehime University, Toon.
Yuki
Y
Tanaka
Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan.
Akiko
A
Komiya
Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan.
Naoshi
N
Fukui
Cell-Free Science and Technology Research Center, Ehime University, Matsuyama, Japan.
Tatsuya
T
Sawasaki
Research and Development Department, Central Blood Institute, Japanese Red Cross Society, Tokyo, Japan.
Kenji
K
Tadokoro
Proteo-Medicine Research Center, Ehime University, Toon.
Masato
M
Nose
Molecular and Genetic Epidemiology Laboratory, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
Naoyuki
N
Tsuchiya
Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan.
Shigeto
S
Tohma
anti-MICA antibody; auto-antibody profile; biological marker; collagen disease; interstitial lung disease